• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Clin Microbiol Infect Dis . Development and evaluation of a serological test for diagnosis of COVID-19 with selected recombinant spike protei

tetano

Editor, Senior Moderator
Eur J Clin Microbiol Infect Dis


. 2020 Nov 12.
doi: 10.1007/s10096-020-04102-4. Online ahead of print.
Development and evaluation of a serological test for diagnosis of COVID-19 with selected recombinant spike proteins


Pingping Zhang[SUP] 1 2 [/SUP], Qi Gao[SUP] 2 3 [/SUP], Tang Wang[SUP] 4 [/SUP], Yuehua Ke[SUP] 5 [/SUP], Fei Mo[SUP] 6 7 [/SUP], Ruizhong Jia[SUP] 5 [/SUP], Wanbing Liu[SUP] 8 [/SUP], Lei Liu[SUP] 8 [/SUP], Shangen Zheng[SUP] 8 [/SUP], Yuzhen Liu[SUP] 9 [/SUP], Luping Li[SUP] 10 [/SUP], Yao Wang[SUP] 11 [/SUP], Lei Xu[SUP] 2 3 [/SUP], Kun Hao[SUP] 2 3 [/SUP], Wei Min[SUP] 2 3 [/SUP], Xiaoli Liu[SUP] 2 3 [/SUP], Ruifu Yang[SUP] 1 2 [/SUP], Shiyue Li[SUP] 12 [/SUP], Changqing Lin[SUP] 13 14 [/SUP], Yong Zhao[SUP] 15 16 [/SUP]



Affiliations

Abstract

Serological test is a valuable diagnostic tool for coronavirus disease 2019 (COVID-19). However, considerable improvements to these tests are needed, especially in the detection sensitivity. In this study, six recombinant nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were prepared and evaluated, including three prokaryotic expression nucleocapsid proteins (rN, rN1, rN2) and three eukaryotic expression spike proteins (rS1, rS-RBD, rS-RBD-mFc). The recombinant proteins with the highest ELISA titers (rS1 and rS-RBD-mFc) were selected to develop a double-antigen sandwich colloidal gold immunochromatography assay (GICA) to detect total antibodies against SARS-CoV-2. The clinical evaluation results showed that the sensitivity and specificity of GICA were 92.09% (419/455) and 99.44% (706/710), respectively. Moreover, a significant number (65.63%, 21/32) of COVID-19 patients with undetectable viral RNA were correctly diagnosed by the GICA method. In conclusion, the eukaryotic expression spike proteins (rS1 and rS-RBD-mFc) are more suitable than the prokaryotic expression nucleocapsid proteins for serological diagnosis of SARS-CoV-2. The proposed GICA for detection of total antibodies could be a powerful complement to the current RNA tests for COVID-19.

Keywords: Colloidal gold immunochromatography assay (GICA); Recombinant protein; SARS-CoV-2; Serological diagnosis.
 
Back
Top Bottom